|
Orthologous residues
|
|
EDG‑1 (human): T236‑p, EDG‑1 (mouse): T236‑p, EDG‑1 (rat): T237‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, western blotting
|
|
Relevant cell lines - cell types - tissues:
CHO (fibroblast) [EphB1 (human), transfection], HUVEC (endothelial), muscle
|
|
Cellular systems studied:
cell lines, primary cells
|
|
Species studied:
hamster, human, mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Akt1 (human)
|
co-immunoprecipitation, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
sphingosin 1-phosphate
|
|
Akt1 (human)
|
|
increase
|
|
|
LY294002
|
sphingosin 1-phosphate
|
|
Akt1 (human)
|
inhibit treatment-induced increase
|
|
|
wortmannin
|
sphingosin 1-phosphate
|
|
Akt1 (human)
|
inhibit treatment-induced increase
|
|
|
IGF-1
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
cell motility, altered, cytoskeletal reorganization
|
|
Comments:
Cortical actin assembly, chemotaxis, and angiogenesis
|
